Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events
- PMID: 23878002
- DOI: 10.1002/eji.201343349
Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events
Abstract
Tumor growth coincides with an accumulation of myeloid-derived suppressor cells (MDSCs), which exert immune suppression and which consist of two main subpopulations, known as monocytic (MO) CD11b(+) CD115(+) Ly6G(-) Ly6C(high) MDSCs and granulocytic CD11b(+) CD115(-) Ly6G(+) Ly6C(int) polymorphonuclear (PMN)-MDSCs. However, whether these distinct MDSC subsets hamper all aspects of early CD8(+) T-cell activation--including cytokine production, surface marker expression, survival, and cytotoxicity--is currently unclear. Here, employing an in vitro coculture system, we demonstrate that splenic MDSC subsets suppress antigen-driven CD8(+) T-cell proliferation, but differ in their dependency on IFN-γ, STAT-1, IRF-1, and NO to do so. Moreover, MO-MDSC and PMN-MDSCs diminish IL-2 levels, but only MO-MDSCs affect IL-2Rα (CD25) expression and STAT-5 signaling. Unexpectedly, however, both MDSC populations stimulate IFN-γ production by CD8(+) T cells on a per cell basis, illustrating that some T-cell activation characteristics are actually stimulated by MDSCs. Conversely, MO-MDSCs counteract the activation-induced change in CD44, CD62L, CD162, and granzyme B expression, while promoting CD69 and Fas upregulation. Together, these effects result in an altered CD8(+) T-cell adhesiveness to the extracellular matrix and selectins, sensitivity to FasL-mediated apoptosis, and cytotoxicity. Hence, MDSCs intricately influence different CD8(+) T-cell activation events in vitro, whereby some parameters are suppressed while others are stimulated.
Keywords: CD8+ T-cell activation; CD8+ T-cell suppression; Monocytic myeloid-derived suppressor cell (MO-MDSC); Nitric oxide; Polymorphonuclear MDSC (PMN-MDSC).
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.Eur J Immunol. 2014 Nov;44(11):3295-306. doi: 10.1002/eji.201344335. Epub 2014 Sep 19. Eur J Immunol. 2014. PMID: 25142017
-
Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.Eur J Immunol. 2009 Oct;39(10):2865-76. doi: 10.1002/eji.200939486. Eur J Immunol. 2009. PMID: 19637228
-
Functional characterization of myeloid-derived suppressor cell subpopulations during the development of experimental arthritis.Eur J Immunol. 2015 Feb;45(2):464-73. doi: 10.1002/eji.201444799. Epub 2014 Nov 28. Eur J Immunol. 2015. PMID: 25352399
-
Modulation of CD8(+) T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells.Immunobiology. 2013 Nov;218(11):1385-91. doi: 10.1016/j.imbio.2013.07.003. Epub 2013 Jul 15. Immunobiology. 2013. PMID: 23932436 Review.
-
Myeloid-Derived Suppressor Cells in Trypanosoma cruzi Infection.Front Cell Infect Microbiol. 2021 Aug 27;11:737364. doi: 10.3389/fcimb.2021.737364. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34513737 Free PMC article. Review.
Cited by
-
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.Front Immunol. 2019 May 3;10:949. doi: 10.3389/fimmu.2019.00949. eCollection 2019. Front Immunol. 2019. PMID: 31130949 Free PMC article. Review.
-
Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer.Discov Oncol. 2023 Oct 19;14(1):185. doi: 10.1007/s12672-023-00793-1. Discov Oncol. 2023. PMID: 37857728 Free PMC article. Review.
-
Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.Invest New Drugs. 2022 Jun;40(3):506-518. doi: 10.1007/s10637-022-01218-6. Epub 2022 Jan 28. Invest New Drugs. 2022. PMID: 35089465 Free PMC article.
-
Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.J Leukoc Biol. 2017 Sep;102(3):727-740. doi: 10.1189/jlb.5VMR1116-458RRR. Epub 2017 May 25. J Leukoc Biol. 2017. PMID: 28546500 Free PMC article. Review.
-
Emergency myelopoiesis in solid cancers.Br J Haematol. 2024 Sep;205(3):798-811. doi: 10.1111/bjh.19656. Epub 2024 Jul 23. Br J Haematol. 2024. PMID: 39044285 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous